<DOC>
	<DOCNO>NCT00058266</DOCNO>
	<brief_summary>RATIONALE : Genistein may stop growth cancer cell block enzymes necessary cancer cell growth . PURPOSE : Phase II trial study effectiveness genistein treat patient localized prostate cancer plan undergo radical prostatectomy .</brief_summary>
	<brief_title>Genistein Treating Patients With Localized Prostate Cancer Who Are Planning Undergo Radical Prostatectomy</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity genistein patient localized prostate cancer treat radical prostatectomy . - Determine decrease , , prostate-specific antigen-positive cell operative field patient treated drug . - Determine quality life patient treated drug . OUTLINE : Patients receive 1 2 treatment regimen . - Group A : Patients receive oral genistein daily 1-2 month , undergo radical prostatectomy , continue oral genistein daily 1-2 month afterward ( total 3 month therapy ) . - Group B : Patients undergo radical prostatectomy . Beginning 1 month surgery , patient receive genistein arm I 3 month . Quality life assess baseline 1 3 month surgery . Patients follow every 3 month . PROJECTED ACCRUAL : A total 88 patient ( 44 patient per treatment group ) accrue study within 2 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis localize prostate cancer Diagnosed within past 6 month T1 T2 disease Gleason score 58 Prostatespecific antigen great 20 ng/mL Radical prostatectomy plan PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy More 2 year Hematopoietic Hemoglobin great 9.0 g/dL Platelet count great 100,000/mm^3 Absolute neutrophil count great 1,000/mm^3 Hepatic SGPT SGOT less 3 time normal Bilirubin le 3 mg/dL ( less 1.5 time normal ) ( patient elevate bilirubin due familial defect bilirubin metabolism consider individual basis ) Renal Creatinine le 2.0 mg/dL Cardiovascular No venous thrombosis within past year Other Patients must use effective barrier contraception No medical condition would preclude study therapy No known soy intolerance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy No concurrent hormonal therapy prostate cancer Radiotherapy Not specify Surgery See Disease Characteristics Other No concurrent soy supplement No concurrent foods high genistein No concurrent active therapy neoplastic disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
</DOC>